TaiGen Entered into an Exclusive License Agreement with YSP to Develop New Drug in Malaysia and Singapore
Shots:
- The companies collaborated to develop and commercialize TaiGen's new drug in Malaysia and Singapore. YSP will be responsible for the NDA and market sales within the authorized region
- Under the terms of collaboration, TaiGen focuses on expanding into the Southeast Asia market & provides a new selection of medication to meet the local medical needs
- TaiGen’s non-fluorinated quinolone antibiotic Taigexyn (Nemonoxacin) received marketing approvals in Taiwan, mainland China, and Russia while the P-II clinical trial of TG-1000 has been completed and out-licensed the development and commercialization rights in mainland China
Ref: PR Newswire | Image: TaiGen
Related News:- TaiGen Entered into an Exclusive License Agreement with Joincare to Develop and Commercialize TG-1000 in China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
